Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia
Paul J. Hampel(Mayo Clinic), Sameer A. Parikh(Mayo Clinic), Amie Fonder, Susan M. Schwager(Mayo Clinic in Arizona), Timothy G. Call(Mayo Clinic), Saad S. Kenderian(Mayo Clinic in Arizona), Amber B. Koehler(Mayo Clinic in Arizona), Daniel L. Van Dyke(Mayo Clinic), Susan L. Slager(Mayo Clinic), Wei Ding(Mayo Clinic), Eli Muchtar(Mayo Clinic), Kari G. Rabe(Mayo Clinic), Esteban Braggio(Dana-Farber Cancer Institute), Yucai Wang(Mayo Clinic), Neil E. Kay(Mayo Clinic), José F. Leis(Mayo Clinic), Thomas E. Witzig(WinnMed)
Cited by 33
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
|JAMA Oncology|2019|829
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2019|735
Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Antibiotic Therapy for Sepsis
|Antimicrobial Agents and Chemotherapy|2010|727
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630